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Abstract
 
Members of the nuclear factor (NF)-
 
k
 
B family of transcription factors play a crucial role in cel-
lular activation, immune responses, and oncogenesis. In most cells, they are kept inactive in the
cytosol by complex formation with members of the inhibitor of NF-
 
k
 
B (I
 
k
 
B) family, whose
degradation activates NF-
 
k
 
B in response to diverse stimuli. In Hodgkin’s lymphoma (HL),
high constitutive nuclear activity of NF-
 
k
 
B is characteristic of the malignant Hodgkin and Reed-
Sternberg (H/RS) cells, which occur at low number in a background of nonneoplastic inflamma-
tory cells. In single H/RS cells micromanipulated from histological sections of HL, we detect
clonal deleterious somatic mutations in the I
 
k
 
B
 
a
 
 gene in two of three Epstein-Barr virus (EBV)-
negative cases but not in two EBV-positive cases (in which a viral oncogene may account for
NF-
 
k
 
B activation). There was no evidence for I
 
k
 
B
 
a
 
 mutations in two non-HL entities or in
normal germinal center B cells. This study establishes deleterious I
 
k
 
B
 
a
 
 mutations as the first re-
current genetic defect found in H/RS cells, indicating a role of I
 
k
 
B
 
a
 
 defects in the pathogen-
esis of HL and implying that I
 
k
 
B
 
a
 
 is a tumor suppressor gene.
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Introduction
 
Hodgkin’s lymphoma (HL) is the most common type of
malignant lymphoma in the Western world. It is distinguished
from other tumors by a peculiar histological presentation:
the giant, often bi- or multinucleated malignant cells, termed
Hodgkin and Reed-Sternberg (H/RS) cells, constitute 
 
,
 
1%
of all cells in the tumor tissue. They are surrounded by an
excess of inflammatory cells, e.g., lymphocytes, macrophages,
and eosinophils, which are believed to be drawn into the
tumor by a deregulated immune reaction precipitated by
the H/RS cells (1).
Investigations into the molecular biology of H/RS cells
are hampered by their scarcity in the tumor tissue. A de-
tailed analysis of their origin was made possible by the
combination of micromanipulation of H/RS cells from
frozen tissue sections with PCR amplification of genes from
single cells (2, 3). Amplification of V(D)J gene rearrange-
ments on the loci coding for IgH and IgL chains revealed
the clonal nature of H/RS cells and their derivation from
mature B cells. Deleterious (“crippling”) somatic mutations
found in some of these rearrangements indicated that the B
cell precursors of H/RS cells resided within the germinal
center, and have acquired the capacity to survive loss of B
cell receptor expression, an event that would otherwise in-
variably lead to death by apoptosis of a germinal center B
cell (4). Consequently, resistance to apoptosis must play a
crucial role in the pathogenesis of the malignant cells.
Despite the impressive progress made in the treatment of
HL, the pathogenesis of the tumor and in particular the
molecular events leading to transformation of the malignant
cells remain to be elucidated. Even though studies on HL-
derived tissue or cell lines suggested that p53 mutations or
bcl-2 translocations might play a role in the pathogenesis of
HL, neither of these ideas could be validated when primary
H/RS cells were investigated (5, 6). In some cases of HL,
the H/RS cells carry EBV and express EBV-encoded pro-
teins such as the oncogenic latent membrane protein 1
(LMP-1 [7]). However, most cases of HL prevalent among
young adults in Western countries are EBV-negative. The
distinct epidemiology of these cases has led to various specu-
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lations about their pathogenesis, but no other virus or recur-
rent transforming genetic defect has been identified to date.
Studies in several HL-derived cell lines identified consti-
tutive nuclear factor (NF)-
 
k
 
B activity as their characteristic
feature (8), suggesting a role for NF-
 
k
 
B in the pathogenesis
of HL. In line with this idea, inhibition of NF-
 
k
 
B activity
in some of these cell lines led to increased susceptibility to
apoptosis and impaired tumorigenicity in nude mice (9).
NF-
 
k
 
B activity is mediated by the Rel/NF-
 
k
 
B family of
transcription factors, members of which are expressed in
virtually all mammalian cells. In most cells, NF-
 
k
 
B is re-
tained in an inactive form in the cytoplasm by binding to
members of the I
 
k
 
B family of proteins (for a review, see
reference 10). A variety of stimuli leads to the degradation
of I
 
k
 
Bs, which allows nuclear translocation of NF-
 
k
 
B and
target gene activation. Most inducible NF-
 
k
 
B responses in
the cell are mediated by the classical NF-
 
k
 
B heterodimer
p50/p65 and are of a transient nature, an effect mainly due
to the rapid resynthesis of I
 
k
 
B
 
a
 
, the prototypic member of
the I
 
k
 
B family. Target genes activated by NF-
 
k
 
B include
factors involved in apoptosis resistance, cell activation, and
proliferation, as well as cyto- and chemokines involved in
immunoregulation (10, 11). In fact, NF-
 
k
 
B has been lik-
ened to a master switch of immune responses, and accumu-
lating evidence indicates in addition a pivotal role of NF-
 
k
 
B
in several pathways of malignant transformation. In lym-
phoid malignancies, for example, NF-
 
k
 
B deregulation may
occur due to chromosomal translocations involving the
 
nfkb2
 
 or 
 
bcl3
 
 loci (11, 12).
In view of this, the demonstration that constitutive ac-
tivity of p65 is also a characteristic feature of the H/RS cells
in primary cases of HL (9) is highly relevant for the patho-
genesis of the tumor. In EBV-positive cases, this NF-
 
k
 
B
activity may be caused by the expression of the viral onco-
gene LMP-1 on the H/RS cells. An intriguing alternative
cause of constitutive NF-
 
k
 
B activity has been proposed on
the basis of data from two HL-derived cell lines, which show
defects in the expression of I
 
k
 
B
 
a
 
 protein (13) due to muta-
tions in the I
 
k
 
B
 
a
 
 gene (14). However, these cell lines have
been established from treated and relapsed patients at late
stages of the disease (15), and it is unclear whether they are
indeed derived from the rare H/RS cells. Likewise, a mu-
tant I
 
k
 
B
 
a
 
 fragment could be amplified from a minute frac-
tion of a partially purified H/RS cell population from a re-
lapsed case of HL (14). Again, it is unclear whether the
mutation is derived from the malignant cells. Even if this
were the case, it is stated by the authors that this mutation
cannot be present in all H/RS cells (14); its relevance for
the NF-
 
k
 
B activity in the H/RS cell clone is thus doubtful.
Therefore, it is an open question whether I
 
k
 
B
 
a
 
 defects
play any role in the pathogenetic process that leads to HL.
For many human malignancies, insight into the mecha-
nisms of tumorigenesis has come from the recurrent detec-
tion of genetic defects that are common to all cells of the
malignant clone and can already be found in primary tu-
mors (rather than sporadic mutations scattered in the tumor
that may arise due to its high mutability or upon treatment).
It is the clonal nature of mutations that implicates their in-
 
volvement in the process of malignant transformation—a
central criterion for the identification of an oncogene or tu-
mor suppressor gene. In this study, we have analyzed the
role of I
 
k
 
B
 
a
 
 defects in HL on the basis of this concept.
 
Materials and Methods
 
Analysis of HL-derived Cell Lines.
 
I
 
k
 
B
 
a
 
 protein was detected
by Western blot with an antibody directed against the COOH
terminus (C-21; Santa Cruz Biotechnology). The I
 
k
 
B
 
a
 
 coding re-
gion was amplified from oligo(dT)-primed cDNA with primers P0S
(5
 
9
 
-AGCGAGGAAGCAGCGCGCAG-3
 
9
 
) and P2AS (5
 
9
 
-AGT-
CCATGTTCTTTCAGCCCC-3
 
9
 
), using the Expand PCR sys-
tem (Boehringer Mannheim) supplemented with 2 mM MgCl
 
2
 
and 2% DMSO. Cycling conditions were 5 min 95
 
8
 
C; 40 cycles
of 50 s at 95
 
8
 
C, 30 s at 63
 
8
 
C, and 90 s at 72
 
8
 
C; and a final 10 min
at 72
 
8
 
C.
 
Primary Cases.
 
The primary cases were as follows: (1) mandib-
ular lymph node biopsy from a 12-yr-old female patient, primary
diagnosis of nodular sclerosing HL; (2) axillary lymph node bi-
opsy from a 20-yr-old male patient, primary diagnosis of nodular
sclerosing HL; (3) supraclavicular lymph node biopsy from a 35-
yr-old male patient, primary diagnosis of nodular sclerosing HL;
(4) cervical lymph node biopsy from a 29-yr-old male patient, re-
lapsed mixed cellularity HL, primary diagnosis was 3 yr prior; and
(5) abdominal lymph node biopsy from a 36-yr-old male patient,
primary diagnosis of mixed cellularity HL.
 
Analysis of Primary Cases.
 
Total genomic DNA was isolated
from sections of the lymph nodes using the QIAamp kit. Single
H/RS cells were micromanipulated from 5-
 
m
 
m histological sec-
tions stained for CD30, and stored in 20 
 
m
 
l of 1
 
3
 
 Expand PCR
buffer (Boehringer Mannheim) at 
 
2
 
20
 
8
 
C. Thawed samples were
incubated with 0.25 mg/ml proteinase K (Boehringer Mann-
heim) for 2 h at 50
 
8
 
C and then 8 min at 96
 
8
 
C. For amplification
of exons 1 and 2, samples were adjusted to 50-
 
m
 
l reaction mixes
supplemented with 2.5 mM MgCl
 
2
 
, 4% DMSO, 50 nM each of
primers I
 
k
 
B1b (5
 
9
 
-TGGTCTGACTGGCTTGGAAATTC-3
 
9
 
)
and I
 
k
 
B1c (5
 
9
 
-CATCGCTGGTCCCCCGGCTC-3
 
9
 
), and 16.6
nM of primers I
 
k
 
B2a (5
 
9
 
-CGAAGTCCCCGGTTGCATA-
AGG-3
 
9
 
) and I
 
k
 
B2c (5
 
9
 
-GGATCTGGGGTGACTCTGC-
TAC-3
 
9
 
). After incubation for 5 min at 95
 
8C, 35 cycles of 50 s
at 958C, 30 s at 658C, and 90 s at 728C were followed by 10
min at 728C. For amplification of exons 3–6, samples were supple-
mented with 2 mM MgCl2, 50 nM each of primers IkB3a
(59-CCTGTCTAGGAGGAGCAGCAC-39), IkB3d (59-TAG-
GAGTTTAAGCTCTTGCCTGGA-39), IkB4b (59-AAAGAAT-
AGGTGAAAGGAGTGAGG-39), and IkB4c (59-ATAAGCAC-
GAGGAGCCTGACTCA-39), and 16.6 nM each of primers
IkB5a (59-AGCAGAAATTCCAAATGCAGCCAT-39), IkB5d
(59-GGAGCAGCTCTAGGGGCCTG-39), IkB6a (59-GAGTTA-
TTTCCAGTAGTGGCCTC-39), and IkB6d (59-GGGGTCAG-
TCACTCGAAGCAC-39). PCR was as above, except that the
annealing temperature was 638C. Seminested amplification of the
individual exons was as follows: for exon 1, the Expand™ PCR sys-
tem was supplemented with 2 mM MgCl2, 4% DMSO, and 125
nM each of primers IkB1b and IkB1r (59-GCGTCCCGCCCT-
CCCGACGA-39); for exon 2, the Expand™ PCR system was sup-
plemented with 2 mM MgCl2 and 125 nM each of primers IkB2b
(59-AGTACAGGTCGTTCCGAGCTGG-39) and IkB2c; exons
3–6 were amplified using standard Taq DNA polymerase in 2 mM
MgCl2; 125 nM each of primers IkB3b (59-AACCAGGAGA-
CACGGGTTGAGG-39) and IkB3d, IkB4b2 (59-GAGGGT-
TGAAACAGGTGGTTAT-39) and IkB4c, IkB5a and IkB5c397 Jungnickel et al. Brief Definitive Report
(59-GGAGGGTGAAGGGAATGGCAC-39), and IkB6b (59-CCC-
ATCCCGGTAGCTTGGCAG-39) and IkB6d were included,
respectively. After 5 min at 958C, 45 cycles of 50 s at 958C, 30 s at
65˚C, and 90 s at 728C were followed by 10 min at 728C. Ampli-
fication of products spanning several exons was performed ac-
cordingly. The same conditions were also used for amplification
of the IkBa exons from total genomic DNA of cell populations
and cell lines. Products were gel-purified and sequenced directly
using the ABI BigDye system.
For amplification of exons 1 and 4 from aliquoted DNA, single
H/RS cells were incubated with 0.25 mg/ml proteinase K (Boeh-
ringer Mannheim) in 120 ml 13 PCR buffer containing 1 ng/ml
5S rRNA and incubated at 508C for 14 h. After gentle mixing by
10 pipetting steps, 20-ml aliquots of the reactions were heated to
968C for 8 min and subsequently adjusted to 50-ml Expand PCR re-
actions supplemented with 2 mM MgCl2, 4% DMSO, 125 nM each
of primers IkB1s (59-CTGAAGAAGGAGCGGCTACTG-39),
IkB1c, and IkB4b, and 62.5 nM of primer IkB5c. After incuba-
tion for 5 min at 958C, 35 cycles of 50 s at 958C, 30 s at 638C, and
90 s at 728C were followed by 10 min at 728C. Seminested am-
plification of exon 1 (the Expand™ system was supplemented with
2 mM MgCl2, 4% DMSO, and 125 nM each of primers IkB1s
and IkB1r) and exon 4 (standard Taq DNA polymerase was used
in 2 mM MgCl2 and 125 nM each of primers IkB4b2 and IkB5c)
was essentially as above.
Analysis of Normal B Cell Populations. Tonsillar mononuclear
cells were sequentially incubated with CD27-FITC (PharMingen)
and anti-FITC microbeads (Miltenyi Biotec), then passed over a
CS-MACS column (Miltenyi Biotec). CD272 cells were sequen-
tially incubated with mouse anti–human IgD (Southern Biotechno-
logy Associates) and anti–mouse IgG2a/b microbeads (Miltenyi
Biotec), and IgD1 cells were isolated via an LS-MACS column
(Miltenyi Biotec). Tonsillar mononuclear cells from the same pa-
tient were incubated consecutively with rat anti–human CD77
(Immunotech), mouse anti–rat IgM (Serotec), and anti–mouse
IgG1 microbeads (Miltenyi Biotec), and CD771 cells were isolated
via an LS-MACS column. Total genomic DNA was isolated from
both cell populations, and exons 1 and 2 of IkBa were amplified
as above using PfuTurbo™ polymerase (Stratagene). After 35 cycles,
PCR products were purified, incubated with 200 mM dNTPs, and
Taq polymerase (GIBCO BRL) for 15 min at 728C, and cloned
into the pGEM-T Easy vector (Promega).
Analysis of Non-HLs. The six IkBa exons were amplified as
above from DNA of peripheral blood lymphocytes (.80% tumor
cells) of chronic lymphocytic leukemia patients (CLL1–6, 9, 10, 13–
15 [16]) and from the Burkitt’s lymphoma cell lines BL31, BL36,
BL41, BL60, BL74 (obtained from G. Lenoir, International Agency
for Research on Cancer [IARC], Lyon, France), Namalwa (from
M. Pawlita, Deutsches Krebsforschungszentrum [DKFZ], Heidel-
berg, Germany), mutu (from M. Falk, Institut für Klinische Molek-
ularbiologie und Tumorgenetik, München, Germany), BJAB (from
E. Kieff, Brigham and Women’s Hospital, Boston, MA), and Ra-
mos (from M. Neuberger, Medical Research Council, Cambridge,
UK). To confirm a germline polymorphism in BL60 (351G®C
on one allele, leading to a Gly®Arg exchange at position 74 in the
IkBa protein), exon 1 was amplified from IARC277, a lympho-
blastoid cell line established from the same patient.
Results and Discussion
A panel of eight HL-derived cell lines was screened for
IkBa defects by Western blot, reverse transcription PCR
amplification and sequencing of IkBa transcripts, and, if
relevant, characterization of the exons of the IkBa gene
(Table I). The reported defects in IkBa protein expression
in two lines (L428, KMH-2 [13]) turned out to be due to
deleterious mutations in one copy of the IkBa gene and
apparent loss of the other copy, in agreement with a recent
study (14). However, all other cell lines (including two not
previously analyzed B lineage–derived lines) harbor wild-
type IkBa transcripts and express full-length IkBa protein.
Notably, the only cell line for which the derivation from
H/RS cells is unequivocally proven (L1236 [17]), expresses
wild-type IkBa from both alleles of the gene, indicating
that IkBa mutations are not present in the H/RS cells in
all cases of HL, if at all. As the limited number and ques-
Table I. Analysis of the IkBa Protein, Transcripts, and Gene in HL-derived Cell Lines
IkBa transcripts
Cell line Origin/EBV status* Full-length IkBa protein Polymorphisms‡ Aberrations‡ Mutations in IkBa gene‡
L428 B/22 175C, 399C, 1049C 893C®U§ 2278C®T§
KMH-2 B/22 175C, 399C, 1049C Del. 509–641
Ins. UCCAGi
Del. 1497–1710
L1236 B/21 175Y, 399C, 1049U –
DEV B/21 175Y, 399C, 1049C –
L591 B/11 175U, 399C, 1049U –
L540 T/21 175U, 399C, 1049Y –
HDLM-2 T/21 175C, 399C, 1049U –
HD-MyZ Myeloid/21 175C, 399U, 1049C –
These sequence data are available from GenBank/EMBL/DDBJ under accession nos. AJ249290 and AJ249291.
*The presumptive origin of the cell lines, as indicated by the presence of rearrangements of the Ig or TCR gene loci, as well as the presence/absence
of EBV in the cells, is given (reference 15).
‡Positions in the cDNA and gene refer to references 18 and 30. Y 5 C/U, R 5 A/G. Del., deletion; Ins., insertion.
§The mutation generates a premature stop codon.
iThe transcript in the line KMH-2 is generated by aberrant splicing that leads to insertion of intronic sequence.398 IkBa Defects in Hodgkin’s Lymphoma
tionable origin of HL-derived cell lines allow no solid con-
clusions on this issue, we turned to the analysis of H/RS
cells from tumor biopsies.
Five cases of HL were chosen for analysis. In two of
them (cases 4 and 5), EBV-encoded small RNA (EBER) in
situ hybridization detected EBV in the H/RS cells. To de-
termine the germline sequence of the coding parts of the
IkBa gene in the patients, DNA was extracted from whole
sections of the infiltrated lymph nodes (i.e., primarily from
the nonmalignant inflammatory cells in the tissue) and used
for amplification and direct sequencing of the six IkBa ex-
ons. Three deviations from the published IkBa sequence
(18) were consistently found in all five cases (738G, 2111T,
2734T), while at another six positions we detected fre-
quent germline polymorphisms (Table II). For determina-
tion of the sequence of the IkBa gene in the malignant
cells, individual H/RS cells micromanipulated from immu-
nostained histological sections were used for seminested
Table II. Sequence Analysis of the IkBa Exons Amplified from Tissue Sections and Single H/RS Cells
Case Exon Polymorphisms* PCR-positive cells‡ Products sequenced Mutations in H/RS cells Alleles amplified§
1 1 212C 2/5 2 Deletion (254–255) 2WT/M
2 1059C 2/5 2 –
3 1678G 5/8 5 –
4 2025C 6/8 6 Deletion (1994) 2WT, 1M, 3WT/M
5 – 6/8 6 –
6 2787T 4/8 1 –
2921A
2 1 212C 7/37 6 –
2 1059T 8/37 8 2 unique mutationsi
3 1678G 5/14 5 –
4 2025C 5/14 5 –
5 – 5/14 5 Deletion (2355–2356) 5WT/M
6 2787C 4/14 4 –
2921G
3 1 212Y 8/26 7 51C®T in 1 seq. 2C, 3T, 2Y
2 1059Y 5/26 5 – 4C, 1T
3 1678R 6/8 6 – 2A, 4G
4 2025Y 5/8 5 – 4C, 1T
5 – 5/8 5 – –¶
6 2787Y 6/8 6 – 4T, 1C, 1Y
2921R 4A, 1G, 1R
4 1 212T 5/12 4 52C®T in 1 seq.
2 1059C 6/12 4 –
3 1678G 5/10 5 –
4 2025C 7/10 6 –
5 – 7/10 6 –
6 2787T 7/10 6 –
2921A
5 1 212Y 8/17 4 – 1T, 3Y
2 1059Y 7/17 7 6 unique mutationsi 4T, 3Y
3 1678R 7/8 5 – 1A, 1G, 3R
4 2025Y 5/8 5 – 3C, 1T, 1Y
5 – 7/8 5 – –¶
6 2787Y 5/8 4 3035G®A in 1 seq. 1C, 3Y
2921R 1G, 3R
These sequence data are available from GenBank/EMBL/DDBJ under accession nos. AJ249283–AJ249289 and AJ249294–AJ249295. seq., sequence.
*Nucleotides at polymorphic sites in the respective exons amplified from the whole tissue DNA. Y 5 C/T, R 5 A/G. Positions in the IkBa gene refer to
reference 18.
‡Two experiments yielding PCR products from negative controls were disregarded.
§Indicates (in cases 1 and 2) amplification of wild-type (WT), mutant (M), or both (WT/M) copies of the respective exon from individual cells, and (in cases
3 and 5) the number of sequences containing either of the two polymorphic nucleotides, or both.
iThe following mutations were each detected in only one of the products of the respective exons. Case 2, exon 2: 942A®G, 1059T®C; case 5, exon 2: 
760C®T, 766G®A, 777C®T, 825T®C, 1004A®C, 1053C®T.
¶Products spanning exons 4 and 5 were amplified. Unmutated exon 5 on both alleles was concluded from the detection of both polymorphic nucleotides at 
position 2025 in unmutated products.399 Jungnickel et al. Brief Definitive Report
PCR amplification. To avoid the detection of mutations
introduced by Taq DNA polymerase, direct sequencing of
the gel-purified PCR products was performed. In most
cases  $4 PCR products of each exon were analyzed, since
the single cell PCR approach may stochastically miss either
of the two copies of the gene in individual reactions.
In case 1, mutations were detected in exons 1 and 4: the
deletion of two and one nucleotides, respectively, leads to
frameshifts (Table II). Both mutations were repeatedly de-
tected in PCR products from H/RS cells (see also Table
III), yet not in the germline sequences of the respective pa-
tient. We conclude that they represent clonal somatic mu-
tations in the malignant cells. Notably, the PCR products
from H/RS cells contain wild-type as well as mutant copies
of the respective exons, indicating the presence of two dis-
tinct alleles of the IkBa gene. To assign the two mutations
to the two alleles, we separated the IkBa loci of H/RS
cells before coamplification of exons 1 and 4. Single H/RS
cells were incubated with protease in buffer, which was
then distributed to six tubes for PCR analysis. Most cells
analyzed contain several copies of both wild-type and mu-
tated exons 1 and 4 (Table III), presumably due to poly-
ploidy, a characteristic feature of H/RS cells (19). Aliquots
with evidence for the presence of more than one copy of
either exon were disregarded. In most other cases, the mu-
tant exon 1 was coamplified with wild-type exon 4, and vice
versa, mutant exon 4 with wild-type exon 1. We conclude
that the two mutations are located on the two different al-
leles of the gene, implying that no full-length IkBa protein
can be synthesized in the H/RS cells. The coamplification
of wild-type exons 1 and 4 in two aliquots (ID, IIIB) is ap-
parently due to amplification of only the wild-type exons
from tubes containing both wild-type and mutated copies.
In case 2, a deletion of two nucleotides, leading to a frame-
shift, was detected in all exon 5 products amplified from the
H/RS cells (Table II). Again, both wild-type and mutant
copies of the exon are evident in the H/RS cells, but no
mutation was seen in the germline sequence. Thus, one of
the two alleles of the IkBa gene in the malignant cells is in-
activated by a somatic mutation. For all other exons, the germ-
line sequence was obtained, but an assignment of these wild-
type products to either of the two alleles is not possible.
Analysis of PCR products spanning exons 3–5 and 5–6, re-
spectively (allowing discrimination of the two alleles due to
the mutation in exon 5), revealed no other point mutation
or deletion in that region in either of the two alleles. Since
exons 1 and 2 could not be included in this analysis (see Ma-
terials and Methods), it is unclear whether the entire coding
region of the second IkBa allele is unmutated. In the third
EBV-negative case (case 3), as well as in the two EBV-posi-
tive cases (cases 4 and 5), no clonal mutations in any of the
IkBa exons were detected (Table II). For cases 3 and 5, we
conclude that all coding exons of both alleles are unmutated,
since germline polymorphisms allow their discrimination.
In several PCR products amplified from the H/RS cells of
cases 2–5, in particular those spanning exons 1 and 2, unique
nucleotide exchanges were detected. They were not seen in
any of the other products of the respective exon of the re-
spective case, and are thus apparently not due to mutations
present in all malignant cells. These mutations might indicate
enhanced mutability of the IkBa gene, reflect the genomic
instability of H/RS cells (20), or be derived from Taq DNA
polymerase errors (although the latter seems unlikely). Be
that as it may, the frequent occurrence of this type of muta-
tion emphasizes an important issue: one can only invoke
clonal genetic defects (i.e., those that can be assigned to all
malignant cells in primary tumors) as an early event in tumor-
igenesis. This is particularly critical in HL, as also nonneo-
plastic cells in the affected patients frequently harbor genetic
aberrations (21). Taking this into account, IkBa mutations
found in an undefined minute cell population from a re-
lapsed tumor (14) or in only a fraction of the H/RS cells are
inconclusive, in particular with respect to the role of IkBa
defects in the pathogenesis of the original tumor.
To assess whether (deleterious) IkBa mutations are fre-
quent in other B cell lymphomas, the six exons of the IkBa
gene were analyzed in a total of 20 non-HL specimens (11
B cell chronic lymphocytic leukemias and 9 Burkitt’s lym-
phoma cell lines; for details, see Materials and Methods).
No mutations were found in any of the samples, suggesting
that IkBa mutations are not common features in these
non-HLs. Since H/RS cells are derived from germinal cen-
ter B cells, we have also assessed whether mutations in the
IkBa gene are frequently introduced in B cells during the
germinal center reaction, as reported for the 59 region of
the bcl-6 gene (22, 23). However, no evidence for an en-
hanced frequency of mutations in germinal center B cells
was found in the 59 region of the IkBa gene (exons 1 and
2), compared with naive B cells and the expected poly-
merase error (Table IV).
In this study, clonal deleterious somatic mutations in the
IkBa gene were detected in the H/RS cells in two of three
EBV-negative and none of two EBV-positive cases of HL.
Reminiscent of the mutations in HL-derived cell lines,
Table III. Analysis of IkBa Exons 1 and 4 Amplified from 
Aliquots of Genomic DNA from Single H/RS Cells of Case 1
I II III IV V
A 1WT 4Mut 1WT 4both 1WT 4Mut
B 1WT 4Mut 1WT 4WT 1WT
C 1Mut 4WT 1WT 4both 1WT 4both
D 1WT 4WT 1both 1WT
E 1both 4WT 1both 4both 1Mut 4WT
F 1Mut 4WT 1Mut 4WT 1WT 4Mut
Five cells (I–V) out of eight analyzed in this experiment yielded PCR
products for exons 1 and 4 in more than one of the six aliquots (A–F).
Sequence analysis of the products revealed wild-type (WT), mutant
(Mut), or mixed (both) sequences for exon 1 and 4, respectively.
Negative control reactions yielded no products for either exon.400 IkBa Defects in Hodgkin’s Lymphoma
they lead to the synthesis of truncated IkBa proteins lack-
ing a part of the ankyrin repeat and/or the COOH-termi-
nal PEST domain (Fig. 1), which are required for interac-
tion of IkB proteins with NF-kB and inhibition of its DNA
binding, respectively (24–26). This suggests that loss or se-
vere impairment of these functions was selected for during
the pathogenesis of the tumor cell clone: it leads to constitu-
tive nuclear activity of NF-kB. The severe phenotype of
IkBa knockout mice indicates that none of the other IkB
family members may fully take over IkBa function (27).
Loss of IkBa function presumably requires the inactiva-
tion of both copies of the gene. In the H/RS cells in most
of the primary cases we investigated, two distinct alleles of
the IkBa gene are clearly detectable, making proof of loss
of function dependent on evidence for inactivation of both
of them. Our single cell PCR approach, which is dictated
by the peculiar histology of HL, does allow the detection
of biallelic gene inactivation in the H/RS cells (in contrast
to a previous one [14]), but it misses several ways of tumor
suppressor gene inactivation, such as large deletions or chro-
mosomal translocations. In light of this, we consider the
detection of three inactivating mutations in the cases stud-
ied, and evidence for loss of IkBa function in one of these
cases, to be a highly significant finding.
The data presented here establish deleterious IkBa mu-
tations as the first recurrent genetic defect found in HL. It
is intriguing that such mutations were only identified in
EBV-negative cases (and lines)—a major subset of this dis-
ease for which no mechanism of transformation could be
pinpointed to date. However, the limited capacity of the
single cell PCR approach does not allow definite conclu-
sions about whether IkBa inactivation is restricted to this
subset, nor about its overall frequency in HL. Our attempts
to analyze a larger panel of cases by specific detection of
full-length IkBa protein in tissue sections failed, due to ap-
parent cross-reactivity of the available antibody against the
IkBa COOH terminus (C-21; Santa Cruz Biotechnology).
Certainly, not IkBa inactivation but rather constitutive
NF-kB (p50/p65) activation may be the unifying feature of
H/RS cells (8, 9, 28), and it may apparently be brought
about by different means. The finding that H/RS cells are
derived from germinal center B cells that may survive the
loss of B cell receptor expression warrants testing of the role
of constitutive NF-kB activation in the rescue of such
“crippled” B cells from apoptosis. Evidently, constitutive
activation of NF-kB (p50/p65) in the context of a B cell
provides an intriguing explanation for several of the dis-
tinctive clinical and pathological features of HL. It likely
precipitates the secretion of a battery of cytokines and
chemokines leading to massive attraction of inflammatory
cells and profound disturbances in immunoregulation, con-
tributes to the peculiar activated phenotype of H/RS cells,
and, most importantly, confers apoptosis resistance and
continuous proliferation as prerequisites of malignant trans-
formation (10–12). The tumorigenic potential of members
of the NF-kB family and of factors inducing NF-kB activ-
ity is well established. In contrast, ex vivo proof of a tumor
suppressor function of an IkB family member has not been
provided to date (but see reference 29). This study gives
evidence for recurrent inactivation of the prototypic IkB
family member, IkBa, in the most common lymphoma of
the Western world. It will be interesting to see whether
functional impairment of IkBs plays a role in the pathogen-
esis of other human malignancies.
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Table IV. Analysis of IkBa Exons 1 and 2 in Normal B Cells
PCR
product
Cell
population
No. of 
sequences
Basepairs
sequenced
No. of 
mutations
Mutation
frequency
%
VH3 rearr. Naive 17 3,253 0 0
GC 13 2,543 135 5.3
IkBa exon 1 Naive 24 10,752 1 0.009
GC 25 11,200 1 0.009
IkBa exon 2 GC 22 9,482 0 0
VH3 gene rearrangements and exons 1 and 2 of the IkBa gene were
amplified from genomic DNA of naive (CD272IgD1) and germinal
center (GC, CD771) B cells, cloned, and analyzed for somatic mutations.
The expected frequency of mutations induced by Pfu DNA polymerase
is 0.0035% (1026 mutations/bp/cycle Pfu DNA polymerase error 3 35
cycles).
Figure 1. IkBa defects in HL. The struc-
ture of the IkBa gene (top; the amplified
regions spanning exons 1–6 are bold, and
translation start and stop codons are given) is
correlated with the structure of the IkBa
protein (bottom; the six ankyrin repeats and
the PEST domain are indicated). The posi-
tions of the mutations detected in H/RS
cells of primary cases, as well as those de-
tected in cell lines, are shown.401 Jungnickel et al. Brief Definitive Report
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Note added in proof. In a recent study of part of the IkBa gene in
H/RS cells, Emmerich et al. (Emmerich, F., M. Meiser, M. Hum-
mel, G. Demel, H.D. Foss, F. Jundt, S. Mathas, D. Krappmann, C.
Scheidereit, H. Stein, and B. Dorken. 1999. Blood. 94:3129–3134) re-
port a clonal monoallelic nonsense mutation in 1 of 10 cases of HL.
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